Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Consensus Price Target from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has earned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $17.25.

Several research analysts recently issued reports on the company. Robert W. Baird cut their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. JMP Securities reiterated a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 26th. Finally, HC Wainwright dropped their price target on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, December 24th.

Insider Activity

In other news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the transaction, the chief executive officer now directly owns 801,638 shares of the company’s stock, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 13.64% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Krensavage Asset Management LLC increased its position in Enanta Pharmaceuticals by 19.7% in the third quarter. Krensavage Asset Management LLC now owns 1,498,074 shares of the biotechnology company’s stock worth $15,520,000 after buying an additional 246,736 shares during the last quarter. Erste Asset Management GmbH purchased a new stake in Enanta Pharmaceuticals in the 3rd quarter worth about $1,243,000. Point72 Asset Management L.P. bought a new stake in Enanta Pharmaceuticals in the 3rd quarter valued at about $903,000. JPMorgan Chase & Co. lifted its holdings in Enanta Pharmaceuticals by 53.7% during the third quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after purchasing an additional 85,082 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Enanta Pharmaceuticals by 34.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock worth $1,109,000 after purchasing an additional 49,050 shares in the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Trading Down 0.2 %

ENTA opened at $5.53 on Monday. Enanta Pharmaceuticals has a 1-year low of $4.71 and a 1-year high of $17.80. The company has a market cap of $117.18 million, a price-to-earnings ratio of -1.01 and a beta of 0.56. The company’s fifty day moving average price is $6.73 and its two-hundred day moving average price is $10.43.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The business had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The company’s revenue was down 22.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.33) EPS. As a group, equities analysts forecast that Enanta Pharmaceuticals will post -4.93 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.